Skip to content
+27 12 743 5959sales@xavant.com

NEWS

Facebook page opens in new windowX page opens in new windowLinkedin page opens in new windowYouTube page opens in new window
Xavant Technology | TOF Monitors, NMT Monitoring, Nerve Mapping
Developers of Quantitative TOF Monitors (NMT Monitors), Nerve Mapping and Locating devices.
Xavant Technology | TOF Monitors, NMT Monitoring, Nerve Mapping
  • Products
  • Videos
  • Online Courses
  • Support
  • About us
  • en_USEnglish
    • es_ESEspañol
    • de_DEDeutsch
  • Products
  • Videos
  • Online Courses
  • Support
  • About us
  • Contact
  • en_USEnglish
    • es_ESEspañol
    • de_DEDeutsch

San Francisco, USA, 13 October 2018 -Xavant Technology (Pty) Ltd is attending the American Society of Anesthesiologists (ASA) Conference 2018 in San Franciso from 13 to 17 October. The company, who is a leading developer of quantitative neuromuscular transmission monitors (NMT monitors) revealed their latest product for the anesthesiology community, the Stimpod NMS450X.

The new device is equipped with their propriety One-Touch NMT technology that enables practitioners to perform full case monitoring from electrode placement to extubation without the need to adjust the device during the procedure.

Learn more about the Stimpod NMS450X here.

By Xavant TechnologyOctober 29, 2018

Related Articles

ASA San Francisco October 2023
October 8, 2023
XPeer Accredited Course
August 20, 2023
ANZCA (ICC Sydney, 5-9 May 2023)
May 1, 2023
V10.5 Software Released!
May 1, 2023
DAC (Dusseldorf, 27-29 April 2023)
April 23, 2023
Vienna Anesthesia Days 2023 (Vienna, 27-29 April 2023)
April 23, 2023
We are leading suppliers of quantitative NMT and TOF monitors for use during general anaesthesia, and peripheral nerve stimulators with nerve mapping and locating for optimal peripheral nerve blocks during regional anaesthesia.
Follow Us
Linkedin-in Youtube
Stay Connected
Join us as we strive to eliminate Residual Neuromuscular Block. Get all the latests products updates and educational tools to achieve this goal in your practice.
Navigate
Menu
  • Distributors
  • Integration Partner
  • Online Courses
  • Blog
  • Support
  • Certificates
  • About us
  • Contact Us
Xavant Technology (Pty) Ltd Unit 102 The Tannery Industrial Park 309 Derdepoort Ave Silverton, Pretoria, South Africa 0184
Privacy Policy | About
Copyright 2023. All rights reserved.

The Stimpod NMS450X+, equipped with two different modalities (AMG and EMG), empowers anaesthesiologists to achieve safer intraoperative control of patients’ neuromuscular blockade. The full case NMT Monitoring enables safe extubation and eliminate residual paralysis in any hospital setting, provider preference and surgery type. This advanced technology empowers clinicians to have a safer and more precise control over the neuromuscular blockade during surgery, aligning with the latest guideline-concordant recommendations for the monitoring of patients for residual paralysis following the administration of a neuromuscular reversal agent. The ASA and ESAIC strongly recommend the use of a quantitative neuromuscular blocking agent monitor in conjunction with neuromuscular blocking agents.

While reversal drugs like Sugammadex are commonly used for NMBA reversal, they are not a foolproof solution and residual paralysis remains a significant concern based on clinical evidence. By incorporating the Stimpod NMS450X+ into their practice, anaesthesiologists can proactively monitor the depth of neuromuscular blockade, significantly reducing the incidence of residual paralysis in patients. This contributes to improved patient outcomes and a safer post-operative recovery.

The Stimpod NMS450X+ offers a cost-effective solution in the OR, PACU and ICU. With its two modalities, AMG and EMG, the device provides flexibility in monitoring options. The only neuromuscular monitoring system available with both AMG and EMG enabling cost control at the point-of-care based on need and specific setting, allowing affordable standardisation across the entire hospital. Cost of Care model, enabling monitoring of all drug usage to ensure optimal use, thus saving on both paralytic and recovery agents. This cost-saving feature ensures efficient resource management without compromising patient safety.

AMG offers the most cost-effective option to implement with a reusable sensor and versatile patient setup options enabling neuromuscular transmission monitoring of the hand, toe or face.

EMG is ideally suited for neuromuscular monitoring of surgeries where tucked hands and arms are required, with optimised performance through a patented, skin-like electrode.

Residual neuromuscular blockade after anaesthesia has been linked to severe complications and adverse outcomes, including increased oxygen desaturation, postoperative pneumonia, airway obstruction, and reintubation. By utilizing the Stimpod NMS450X+ and effectively preventing residual NMB, clinicians can contribute to reduced LOS in hospitals and improve patient recovery rates.

Anaesthesiologists worldwide who have adopted the Stimpod NMS450X+ demonstrate their commitment to following the latest guidelines and best practices in anaesthesia. By incorporating a quantitative NMBA monitor into their practice, clinicians align themselves with the recommendations set forth by the ASA and ESAIC, promoting a higher standard of care and patient safety. By utilizing the Stimpod NMS450X+, anaesthesiologists are a testament to its effectiveness to improve patients outcomes and can contribute to the reduction of adverse events and enhance the recovery process for their patients.

This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.I agreeCookie policy